

1/7




Figure 1

2/7




Figure 2a : In vitro release profiles for 2 Gelucire®-based microcapsule formulations (1G5, 3G5), containing 5 % hGH core microparticles. The % protein released is calculated based on the experimentally determined hGH loading of the microcapsules.

3/7




Figure 2b : In vitro release profiles for a Gelucire[®]-based microcapsule formulation with 10% payload hGH microparticles. The release profile is shown calculated with respect to the experimentally determined hGH loading

4/7




Figure 3 : In vitro release profiles for 2 Precirol®-based microcapsule formulations (1P5, 5P5). The % protein released is calculated based on the experimentally determined hGH loading of the microparticles.




Figure 4 : In vitro release profiles for one Precirol®/Gelucire®-based formulation (1GP5). The % protein released is calculated based on the experimentally determined hGH loading of the microparticles.

6/7

FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT SLCFSESIPT
60
PSNREETQOK SNLELLRISL LLIQSWLEPV QFLRSVFANS LYGASDSNV YDLLKDLEEG
120
IQTLMGRLED GSPRTGQIFK QTYSKFDTNS HNDDALLKNY GLLYCFRKDM DKVETFLRIV
5 180
QCRSVEGSCG F

Fig. 5: Amino acid sequence of human growth hormone

10

15

20

25

30

7/7




Figure 6 : In vitro release profiles for microcapsule formulations (DM5, GP5b, D5, DM10). The % protein released is calculated based on the experimentally determined hGH loading of the microparticles.